Background: Experts express reluctance to hospitalize patients with borderline personality disorder (BPD) for more than a few days, arguing that extended inpatient care leads to deterioration and adverse events. To date, there is no empirical support for these assertions. Aims: The current study examined the assumption of iatrogenic effects among BPD adults. Methods: Clinically significant and reliable change in symptoms, functional capacities, and adverse events were quantified for both inpatients with BPD (n=245) and a well-matched inpatient reference (n=220) sample. Latent growth curve (LGC) models were used to evaluate moderators of the trajectory of PHQ-9 depression scores over the course of hospitalization. Results: Large effect size improvements were observed in depression, anxiety, suicidal ideation and functional disability among patients with BPD (Cohen's d ≥ 1.0) and those in the reference sample (Cohen's d ≥.80). Clinical deterioration and adverse events were rare (occurring in no more than 1.1% of BPD and reference patients on any outcome) with no difference across patient cohorts. BPD diagnosis failed to influence the trajectory of continuous depression severity. Rather, trait emotion dysregulation was associated with initial depression severity. Conclusions: Twenty-five years ago it was assumed that adults with BPD could not benefit from psychiatric treatment. Today there are a number of effective evidence-based outpatient treatments for BPD, but beliefs about extended inpatient treatment have changed little. Current results indicate that extended inpatient treatment can result in significant and clinically meaningful symptomatic and functional improvement in BPD patients without iatrogenic effects.
Borderline personality disorder (BPD) is the most extensively studied personality disorder (1-3); however, knowledge gaps persist, especially in the area of inpatient treatment course and outcome.
This gap is particularly problematic because 1. Adults with BPD utilize inpatient and emergency department services at a higher rate than any other psychiatric group and far more than individuals with depression (4), and 2. Psychiatry is polarized over the utility of extended hospitalization for adults with BPD. Many BPD experts warn against hospitalizing patients with BPD for more than a few days due to concerns that extended hospitalization will lead to significant deterioration (5) (6) (7) (8) (9) . Dawson and MacMillan warn clinicians never to hospitalize borderline patients (5) , while Paris strongly advises against hospitalization, concluding that hospital admissions are designed to treat episodic mood disorders and psychosis, but not persistent mood or suicidal conditions (9) . Paris has a point-the vast majority of short-term psychiatric units in the US and Canada are designed for stabilization and may not be suitable for BPD patients; however, the tautology carelessly extends beyond acute hospital units and ignores the existence of extended hospital programs in European countries and the US. Further, such provocative proclamations appear to be based purely on anecdotal evidence, given the absence of published scientific evidence of functional variations during the course of extended hospital treatment, or in particular demonstrating deterioration in functioning in patients with BPD. Complicating matters, practice guidelines (10-12) specifically include indications for hospitalization (in the context of steppedcare based on least restrictive, cost-effective care for current functional impairment). The American Psychiatric Association Practice Guideline for the Treatment of Patients with Borderline Personality Disorder (10) advances a set of indications for extended hospitalization:
1. Persistent and severe suicidality, self-destructiveness, or nonadherence to outpatient treatment or partial hospitalization, 2. Comorbid refractory axis I disorder (e.g., eating disorder, mood disorder) that presents a potential threat to life, 3. Comorbid substance abuse or dependence that is severe and unresponsive to outpatient treatment or partial hospitalization, 4. Continued risk of assaultive behavior toward others despite brief hospitalization, and 5. Symptoms of sufficient severity to interfere with functioning, work, or family life that are unresponsive to outpatient treatment, partial hospitalization, and brief hospitalization (pg. 13).
While the APA guideline for extended hospitalization is logical and consistent with the stepped-care model, the advice appears based on clinical wisdom, to prevent further deterioration and/or death, rather than based on evidence that extended hospitalization is an effective intervention for individuals diagnosed with BPD.
Absent empirical evidence, contemporary clinicians have no way of assessing the relative merits of extended hospital care for BPD. Is it a potential iatrogenic disaster (alternatively, as some experts insist, a costly inert ingredient that postpones effective care) or can it be an effective treatment option?
The current study examined symptom trajectories including remission and deterioration rates on measures of depression, anxiety, suicidal ideation, functional disability, and well-being among psychiatric inpatients with BPD (n=245) compared to matched reference inpatients (n=220). Incidents of suicide attempts and non-suicidal self-injury (NSSI) during hospitalization were compared as direct behavioral indicators of deterioration.
Hypotheses
If Iatrogenic effects are prevalent among BPD inpatients, results would indicate elevated severity of symptoms and impairment in functioning with marked spikes in symptom severity for BPD patients measured at bi-weekly intervals, and flat treatment response (higher initial symptom severity, limited improvement) relative to a reference inpatient sample. Similarly, remission rates should be substantially lower for the BPD cohort compared to a matched reference sample, particularly in light of the adverse impact that co-occurring personality disorders can have on remission rates from major depression (13) , By contrast, a reference inpatient sample would be expected to evidence large effect size reductions in symptoms, and improvement in functioning, consistent with recent studies from this inpatient setting (14) (15) (16) (17) . In the event that BPD patients evidenced equivalent rates of improvement and/or deterioration to the reference sample, we planned to explore baseline moderators of depression change (BPD diagnosis, substance use disorder, history of interpersonal trauma, emotion regulation).
Methods

Treatment Characteristics
Services were provided (June 2012-September 2015) through a specialized, extended inpatient psychiatric facility in the United States. Treatment programming was organized around a mentalizationbased therapeutic model (18) 
Procedures
Data were collected as part of the hospital's ongoing Adult Outcomes Project to assess treatment response (19) . Measures were collected within 72 hours of admission and were readministered every 14 days during hospitalization and at point of discharge. This study was approved by the Institutional Review Board of Baylor College of Medicine. Propensity score matching (PSM) was used to match 245 BPD patients receiving between two and eight weeks of inpatient care with a cohort of reference patients from this facility without BPD. A propensity score pairs subjects from the case group (BPD) with subjects from the reference group such that the overall distribution of baseline potential confounds is similar across groups (20, 21) . This procedure increases the probability that results are due to primary dependent variables (in this case the presence/absence of BPD) rather than baseline confounds (20) . The PSM procedure identified 220 reference inpatient controls that matched on age, gender, history of prior psychiatric hospitalization, number of psychiatric disorders, and length of hospitalization. Average length of stay (LOS) for the total sample was 40.7 days (SD= 13.9). Exclusion criteria were restricted to length of stay ≤ 14 days and ≥ 57 days (consistent with the design of the treatment program). Characteristics of the BPD and matched reference patients are provided in Table 1 .
Measures
Demographic variables were assessed using a standardized patient information survey (15) .
Trauma-related events were assessed using a modified 14-item version (22) .94). All suicide attempts (SA) and NSSI were coded based on extant record of events as an ongoing internal safety and quality improvement project. Due to low prevalence rates, individual counts for SA and NSSI were summed over the course of hospitalization.
Data Analysis
Treatment Gains and Deterioration
Therapeutic gains, symptom deterioration, and adverse events (from intake to discharge) were quantified through several metrics for both cohorts. Confidence intervals for within-group change and corresponding effect sizes provided estimates for the magnitude of expected treatment response in those receiving care through this facility. Clinically significant change was operationalized as discharge scores falling closer to the mean of a functional sample relative to the original clinical population (37) .
Finally, indices of reliable change were calculated to detect symptom fluctuations (both improvement and deterioration at each assessment point) exceeding those attributable to measurement error alone (37) . Reliable change is commonly employed as a metric of patient deterioration in the existing treatment literature (38, 39) .
Moderators of Continuous Recovery
Latent growth curve (LGC) models were used to evaluate moderators of the trajectory of PHQ-9 depression scores over the course of hospitalization. In this approach, patient-specific trajectories are aggregated to form a baseline model of overall recovery. Predictors of patient-specific change are incorporated in cases where growth parameters in the baseline model provide evidence of variability in the trajectory of recovery across individuals. A stepped approach was used for the current analyses (40) . Analyses were conducted using MPlus 6.1 software with maximum likelihood (ML) estimation (41) . A notable feature of ML is the ability to accommodate cases with partially missing values. For the current sample, missingness in bi-weekly scores was due primarily to differences in LOS across the 8week treatment window (i.e., cases with longer hospital stay recorded a greater number of assessments than those with shorter hospitalizations). Given that (a) missing data at later assessments were a direct function of length of stay, and (b) length of stay was explicitly modeled in the larger analyses, data loss was assumed to meet standards for missing at random (MAR) and appropriate for ML estimation (42) .
Model Fit. Model adequacy was evaluated using comparative fit index (CFI), Tucker-Lewis index (TLI), and root-mean-square of approximation (RMSEA) values. For these analyses, CFI and TLI > .90, and RMSEA < .08 were considered evidence of adequate fit (43) (44) (45) . CFI and TLI > .95 and RMSEA < .06 were interpreted as indicative of close fit (45) .
Results
Sample Characteristics
Patients presenting with a diagnosis of BPD evidenced greater symptom and functional impairment (see Table 1 ) at intake relative to reference patients (all p ≤ .001), with between-group effects falling in the small-to-medium range. BPD patients continued to evidence incrementally greater impairment at discharge (all p ≤ .020), although data indicate a consistent reduction in the discrepancy between BPD and reference sample functioning.
Pre-to Post-Treatment Gains
Similar trajectories of recovery were observed across BPD and reference groups (see Fig. 1 ) for all measures over the 8-week treatment window. Absolute change from intake to discharge was substantial in both samples (see Table 2 ). Reference patients demonstrated a .81 to 1.15 standard deviation improvement across all clinical outcomes. Lower limits of corresponding confidence intervals exceeded standard benchmarks for large effects (46) with the exception of change in suicidal ideation.
Absolute change in patients with a diagnosis of BPD was more pronounced. Point estimates of effect and lower limits of corresponding confidence intervals indicated, at minimum, a full standard deviation improvement across all outcomes. Rates of clinically significant change were comparable across groups (see Table 3 ) based on non-clinical distributions for the PHQ-9 (47), GAD-7 (27), WHO-DAS 2.0 (48), and WHO-5 (49) . Small to medium effects were noted in the occurrence of reliable change, however, with BPD patients demonstrating more frequent improvement in PHQ-9 (p < .001), GAD-7 (p = .001), WHO-5 (p < .001), and C-SSRS (p = .058) scores. Deterioration in symptoms over the course of hospitalization was rare, occurring in no more than 1.1% of BPD and reference patients on any outcome. There were no suicide attempts for either group. Prevalence of NSSI was low for both BPD (9 of 245: 3%) and reference (2 of 220: 1%) samples with no overall differences (χ 2 =2.7, p=.10).
Growth Models
Baseline linear and quadratic models were examined to determine the overall shape of change in depression severity. Loadings for growth parameters were weighted to reflect time (in weeks) since admission. Growth parameters in baseline models were regressed onto LOS (mean centered) to account for variability in the duration of hospitalization. Bootstrapped standard errors were estimated using 500 redraws from the original sample. Estimation of the full quadratic model offered further support for homogeneity of change (see Supplemental Table 4 ). Although inclusion of patient-specific factors produced notable improvements in overall model fit (CFI = .975, TLI = .994, RMSEA = .044, CI90% [.023, .064]), moderating effects were limited to the prediction of initial depression (intercept). Alcohol/substance use disorders were associated with lower PHQ-9 scores at admission (β = -.126, p = .011) whereas initial depression was more severe among patients reporting a history of interpersonal trauma (β = .114, p = .019). BPD status failed to evidence independent relations with recovery parameters controlling for other variables in the model. An interactive effect of BPD diagnosis and initial affect dysregulation was noted, however, in the prediction of depression scores at admission (β = -.128, p = .011). Follow-up tests indicated elevated depression among BPD patients relative to reference patients only within the context of low dysregulation (β = .191, p = .027). Initial PHQ-9 scores were similar in BPD and reference patients reporting (see Figure 2 ) elevated emotional dysregulation (β = -.088, p = .226). Slope and quadratic parameters in the final model were unrelated to BPD status, trauma history, or DERS scores at admission (p ≥ .102).
Discussion
Borderline personality disorder (BPD) is characterized by emotion dysregulation, impulsivity, self-injurious behavior, and suicidal behavior all of which contribute to the highest emergency and inpatient service utilization of any psychiatric disorder (4) . The prevalence of BPD is estimated to range from 10 percent in outpatient clinics to between 15 and 25 percent in inpatient settings (2) . High- Furthermore, linear growth model trajectories indicated that BPD diagnosis did not impact change in depression severity during the course of treatment. An interactive effect of BPD diagnosis and baseline emotion dysregulation did emerge with respect to depression scores assessed at intake. Here, BPD diagnosis was associated with elevated levels of initial depression, but only within the context of low emotion dysregulation. Individuals presenting for treatment with high levels of baseline dysregulation evidenced similar depression scores, irrespective of BPD status.
The results of growth modeling highlight the impact of the initial severity of emotion dysregulation on baseline depression severity, as well as differential end-point functioning. As can be seen in Figure 2 , BPD and reference inpatients with high levels of emotion dysregulation manifested differential depression severity from those with lower emotion dysregulation. Emotion dysregulation, as we have argued elsewhere (56) , may represent a cross-cutting dimension of psychopathology that exerts significant influence on baseline symptom expression and treatment response, regardless of primary diagnosis. In this vein, the NIMH RDoC initiative (57) with its emphasis on underlying cross-cutting dimensions of psychopathology may provide a better model for understanding patients at risk for attenuated treatment response.
Finally, the large effect size improvements for BPD inpatients across symptom and functional domains were surprising. While beyond the scope of the study design to explore mechanisms of change, there are several treatment features at the study institution worth noting. First, BPD inpatients were in a contained and secure environment in which self-defeating and self-destructive behaviors (such as alcohol and drug abuse) were minimized, and medication adherence for both groups was approximately 99% for all standing psychotropic orders. The volume of therapeutic encounters (an average of 59 hours of active programming per week) is far beyond community-level treatment as usual and may be a significant factor in treatment response. Finally, the mentalization-based treatment may have been particularly well-suited for the BPD sample.
The large sample of BPD inpatients (n = 245) with research confirmed diagnoses, systematic assessment of treatment response, and well-matched reference sample are strengths of the current study. Nonetheless, several limitations are noteworthy. The sample does not include outpatient controls and is comprised of individuals with severe mental illness with relatively high levels of PD traits. It is clear from the literature that outpatient treatment can be effective for many patients with BPD.
However, for patients with BPD who have complex illnesses that have not responded to outpatient treatment, intensive extended inpatient treatment can be highly beneficial. Finally, it is important to note that our study did not assess post-discharge functioning, which is a significant limitation--data are currently being collected on post-discharge patients.
The expected differences between reference and BPD groups did not emerge perhaps in part because confounds of age, gender, history of prior psychiatric hospitalization, co-occurring psychiatric disorders, and length of hospitalization were controlled through the PSM procedure. It seems plausible that prior observations of iatrogenic effects for BPD inpatients were due to comorbid conditions or a lack of structured, evidence-based treatment. With over 250 variations within the BPD diagnosis (57), it has long been established that two individuals diagnosed with BPD can manifest extremely different levels of psychopathology and treatment response-in that light, experts advocating against extended hospitalization of BPD patients may base such global assertions on particularly salient memories of adverse outcomes among a limited set of BPD inpatients (a case of Berkson's bias). Third, some extended inpatient settings may induce iatrogenic effects such as those noted by Paris (9) . Inpatient settings with a lack of clear structure and expectation inevitably lack systematic delivery of contemporary evidence-based treatments for BPD and thus may create invalidating environments that may be particularly prone to iatrogenic effects (8) . a Criteria for clinically significant change in reference patients were scores at or below 6.0, 6.0, and 7.0 on the PHQ-9, GAD-7, and WHO-DAS, and 11.0 or above for the WHO-5; criteria for PBD patients were scores at or below 8.0, 7.0, and 9.0 on the PHQ-9, GAD-7, and WHO-DAS, and 10.0 or above for the WHO-5; clinically significant change for C-SSRS was not calculated given the absence of non-clinical scores for this measure Note: 
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